ClinicalTrials.gg
CompletedNCT02007941Updated Dec 6, 2016

Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects

A Phase 1 interventional study of CKD-501 in Renal Impairment and Healthy, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-06.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Renal Insufficiency with a site in Korea, Republic of — 4 open to participants now, 5 under way, none of them phase 3. Renal Insufficiency · Korea, Republic of.

Enrollment
23rd of 29
28 · median 209
Started
2014
with 1 other
Phase 1
10 of 35
none open now
Registered
18th of 35
by date

Among the 35 studies in Renal Insufficiency with a site in Korea, Republic of, this one is the 23rd largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 in phase 1, and was the 18th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

4 of the 35 studies in Renal Insufficiency with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Renal Insufficiency with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to assess between the renal impaired patients and normal renal function subjects comparetive evaluation to Pharmacokinetics after CKD-501 Future, When prescription CKD-501 to renal impaired patient, It will be guidelines to provide a basis of instructions.

Read the detailed description

A Phase 1, Non-randomized, Open, Parallel-Group Clinical trial

03

Conditions studied

  • Renal Impairment
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  • Adult males or females, 20 - 65 years of age (inclusive);
  • (BMI) range of approximately 18.5-29.9 kg/㎡ (inclusive);
  • Agreement with written
  • Agree to Medically acceptable method of during clinical trials

Normal Renal Function subjects:

  • Matched to renal impaired patients(ESRD) in the study by age (±7 years), sex and BMI
  • Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical history, , physical examination);
  • ≥ 90 mL/min/1.73mE2;

Renally impaired subjects:

  • Matched to renal impaired patients(ESRD) in the study by age (±7 years), sex and BMI
  • Subjects with mild renal impairment (eGFR 60-89 mL/min/1.73mE2) OR moderate renal impairment (eGFR 30-59 mL/min/1.73mE2) OR severe renal impairment (eGFR 15-29 mL/min/1.73mE2) OR dialysis end stage renal disease(ESRD)

Exclusion criteria

Exclusion Criteria

All subjects:

  • The subject's systolic blood pressure is outside the range of 100-180mmHg, or diastolic blood pressure is outside the range of 50-110mmHg
  • Repeatedly Screening parameters (PR ≥ 210 mse,QRS ≥ 120 msec, ≥ 500 msec)
  • Repeatedly lab( >1.25xULN, ALT>1.25xULN ,Total >1.5xULN)
  • A positive pre-study drug screen.(amphetamines, barbiturates, cocaine, opiates, cannabinoids, benzodiazepin)
  • allergic diseases or History of thiazolidinedione class's anaphylaxis reactions
  • Can not stop to be taking caffeine (caffeine > 400mg/day), drinking(alcohol > 30 g/day) or severe heavy smoker(cigarette > 10 cigarettes/day) during clinical trials
  • Consumption of food which may affect study within 7 days prior to first dose of study medication or taking a dietary supplement now or continued.
  • Consumption of drug which may affect study within 7 days prior to first dose of study medication.
  • Previously donate whole blood within 60 days or component blood within 30 days prior to first dose of study medication.
  • blood transfusion within 30 days prior to first dose of study medication.
  • Subjects with participation in another clinical trial within 60 days prior to the study
  • An impossible one who participates in clinical trial by Principal investigator's decision

Normal Renal Function subjects:

  • Subjects with a history of chronic disease or an acute illness within 28 days of study medication administration
  • Subjects with a history of gastrointestinal disease effected study medication or surgery(except appendectomy, hernia surgery)
  • Current or chronic history of liver disease or ascites or hepatic encephalopathy

Renally impaired subjects:

  • Type I diabetes, Diabetic ketoacidosis, diabetic coma or a history of coma (controllable Type II diabetes including possible)
  • Uncontrollable hypertension or severe heart failure
  • require treatment with or drug
  • History of renal transplant or undergoing other dialysis method except hemodialysis
  • Needs treatment for acute disease, uncontrolled other disease or diabetic complications
  • Current or chronic history of liver disease or ascites or hepatic encephalopathy
  • Subjects with a history of chronic disease or an acute illness within 28 days of study medication administration
  • Subjects with a history of gastrointestinal disease effected study medication or surgery(except appendectomy, hernia surgery)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    End Stage Renal Disease(ESRD)

    CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15. First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress

    Drug: CKD-501

  • Active comparator
    normal renal function

    CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more. First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress

    Drug: CKD-501

  • Experimental
    Mild renal impairment

    CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.

    Drug: CKD-501

Interventions

  • From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .

    Also known as: Lobeglitazone

06

What researchers measure

Primary outcomes

  1. The pharmacokinetic( Cmax, AUCt ) of lobeglitazone(CKD-501) Between Renal Impaired patients and Normal Renal function subjects

    * Blood sampling timepoint : (Day 1) 0hr, 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 3hr, 6hr, 12hr, 24hr (Day 2)36hr (Day3)48hr- total 12 timepoints per period * Additional Blood sampling for unbound fraction analysis : (Day 1) 1hr, 6hr, 12hr * Urine collection : (Day 1)0-6hr, 6-12hr, 12-24hr (Day 2) 24-36hr, 36-48hr

    Time frame: 0-48 hrs

Secondary outcomes

  1. The pharmacokinetic( Cmax, AUCt ) of main metabolites(M7) of CKD-501 Between Renal Impaired patients and Normal Renal function subjects

    * Blood sampling timepoint : (Day 1) 0hr, 0.33hr, 0.66hr, 1hr, 1.5hr, 2hr, 3hr, 6hr, 12hr, 24hr (Day 2)12hr (Day3)0hr- total 12 timepoints per period * Urine collection : (Day 1)0-6hr, 6-12hr, 12-24hr (Day 2) 24-36hr, 36-48hr

    Time frame: 0-48 hrs

07

Study locations

1 site
  • The Inje University Busan Paik Hospital
    Busan, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 11, 2013
Start
Apr 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Dec 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02007941
Responsible party
Sponsor
First posted
Dec 11, 2013
Start date
Apr 2014
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Dec 6, 2016

Study contacts

Jae Kuk Shin, Ph.D. M.D
principal investigator · The Inje University Busan Paik Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion